XRCC1 polymorphisms that reduce BER recruitment to these sites would reduce interference with the nucleotide excision repair pathway, allowing more effective repair of the DNA adduct and increasing cancer cell resistance to the drug. The gene discussed is XRCC1; the disease is cancer.